放化疗后不可切除Ⅲ期非小细胞肺癌巩固治疗:benmelstobart 联用或不联用 anlotinib 的 R-ALPS 试验解读

Evaluating Benmelstobart With or Without Anlotinib as Consolidation Therapy After Chemoradiotherapy in Unresectable Stage III NSCLC: Insights from the R-ALPS Trial

The R-ALPS randomized trial confirms that benmelstobart improves progression-free survival in unresectable stage III NSCLC patients post-chemoradiotherapy, while adding anlotinib does not significantly enhance efficacy and raises severe toxicity risks.
Perioperative Toripalimab Enhances Surgical Outcomes and Survival in Stage III Resectable NSCLC: Insights from the Neotorch Trial

Perioperative Toripalimab Enhances Surgical Outcomes and Survival in Stage III Resectable NSCLC: Insights from the Neotorch Trial

This post hoc analysis of the Neotorch phase 3 trial demonstrates that adding toripalimab to chemotherapy perioperatively in stage III resectable NSCLC improves tumor and nodal downstaging, reduces surgery cancellation, and significantly enhances event-free survival without increasing surgical complications.